Manufacturers report positive results for trastuzumab duocarmazine in the phase III TULIP study in HER-2 positive advanced breast cancer
In the study of 436 patients who had progressed following two or more HER2-targeting treatment regimens for locally advanced or metastatic breast cancer, this antibody-drug conjugate was reported to improve progression free survival vs physicians choice of treatment.
Source:
Biospace Inc.